Motixafortide
Also referenced as: Aphexda
A cyclic peptide CXCR4 antagonist used to mobilize hematopoietic stem cells.
- Evidence grade
- BModerate Human Evidence
Moderate Human Evidence
- Regulatory status
- FDA Approved for Specific Indication
Aphexda is FDA-approved with filgrastim for stem-cell mobilization, collection and subsequent autologous transplantation in multiple myeloma.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A cyclic peptide CXCR4 antagonist used to mobilize hematopoietic stem cells.
Aphexda is FDA-approved with filgrastim for stem-cell mobilization, collection and subsequent autologous transplantation in multiple myeloma.
Mobilization for transplantation is not a direct anticancer treatment, regenerative wellness therapy or stem-cell rejuvenation claim.
Why It's Being Studied
- Stem-cell mobilization
- Multiple myeloma transplant preparation
- CXCR4
Mechanism of Action
Disrupting CXCR4-related marrow retention releases stem cells into circulation for collection.
Disrupting CXCR4-related marrow retention releases stem cells into circulation for collection. Mobilization for transplantation is not a direct anticancer treatment, regenerative wellness therapy or stem-cell rejuvenation claim.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Stem-cell mobilization
- Multiple myeloma transplant preparation
- CXCR4
- Subcutaneous approved medicine
Evidence Summary
Randomized evidence supports stem-cell mobilization with filgrastim in multiple myeloma transplant preparation.
Higher tiers carry more weight. Filled tiers have evidence for Motixafortide; tap to read it.
- Randomized evidence supports stem-cell mobilization with filgrastim in multiple myeloma transplant preparation.
1 cited sources.
- Regulatory document1
Human clinical evidence
- Randomized evidence supports stem-cell mobilization with filgrastim in multiple myeloma transplant preparation.
Reported Adverse Events in Research
- Hypersensitivity, anaphylaxis and injection-site reactions are important risks.
Limitations of Current Evidence
- Mobilization for transplantation is not a direct anticancer treatment, regenerative wellness therapy or stem-cell rejuvenation claim.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Motixafortide | Trofinetide | |
|---|---|---|
| Evidence grade | B — Moderate Human Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous approved medicine | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Regulatory document
Motixafortide — regulatory document